SMR 2024 | IGNYTE: RP1 with nivolumab in anti-PD1-resistant melanoma
Gino In, MD, University of Southern California, Los Angeles, CA, shares results from the Phase I/II IGNYTE trial (NCT03767348) of vusolimogene oderparepvec (RP1) in patients with advanced melanoma unresponsive to prior anti-PD1 therapy. The trial involved a cohort of 140 patients who received a single dose of RP1 followed by a combination of RP1 and nivolumab, a PD-1 inhibitor, of up to 8 doses. RP1 demonstrated good efficacy and safety, which provides a promising novel approach for the treatment of high-risk advanced melanoma. This interview took place at the 21st International Congress of the Society for Melanoma Research (SMR) in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
